| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000021203 |
| Receipt No. | R000024177 |
| Official scientific title of the study | NAVIGATE: Clinical Evaluation of superDimension Navigation System for Electromagnetic Navigation Bronchoscopy |
| Date of disclosure of the study information | 2016/03/01 |
| Last modified on | 2017/06/01 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | NAVIGATE: Clinical Evaluation of superDimension Navigation System for Electromagnetic Navigation Bronchoscopy | |
| Title of the study (Brief title) | NAVIGATE: Clinical Evaluation of superDimension Navigation System for Electromagnetic Navigation Bronchoscopy | |
| Region |
|
|
| Condition | |||
| Condition | Lung Lesion(s) Requiring Evaluation | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | The purpose of this study is to evaluate outcomes following electromagnetic navigation bronchoscopy(ENB) procedures using the superDimension navigation system. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Incidence of pneumothorax related to the index procedure rated as Grade 2 or higher according to the Common Terminology Criteria for Adverse Events (CTCAE) scale. |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.Subject presents with lung lesion(s) requiring evaluation
2.Subject is willing and able to provide informed consent to participate in the study 3.Subject is candidate for elective ENBprocedure 4.Subject is over the age of 20 |
|||
| Key exclusion criteria | 1.The subject is unable or unwilling to comply with study follow-up schedule
2.The subject has participated in an investigational drug or device research study within 30 days of enrollment that would interfere with this study 3.Female subjects who are pregnant or nursing as determined by standard site practices |
|||
| Target sample size | 180 | |||
| Research contact person | |
| Name of lead principal investigator | Hideo Saka |
| Organization | Nagoya Medical Center |
| Division name | Department of medical Oncology |
| Address | 4-1-1, Sannomaru, Naka-ku, Nagoya, Aichi, Japan |
| TEL | 052-951-1111 |
| saka@med.nagoya-u.ac.jp | |
| Public contact | |
| Name of contact person | Hiroaki Kato |
| Organization | Covidien Japan Inc. |
| Division name | Medical Affairs |
| Address | 4-10-2, Yoga, Setagaya-ku, Tokyo, Japan |
| TEL | 03-5717-1700 |
| Homepage URL | |
| hiroaki.kato@medtronic.com | |
| Sponsor | |
| Institute | Covidien Japan Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Covidien Japan Inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | YES |
| Study ID_1 | NCT02410837 |
| Org. issuing International ID_1 | ClinicalTraials.gov |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 東京医科大学(東京都)
日本医科大学(東京都) 国立がん研究センター中央病院(東京都) 聖マリアンナ医科大学(神奈川県) 名古屋医療センター(愛知県) 京都大学(京都府) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | Evaluate outcomes following electromagnetic navigation bronchoscopy (ENB) procedures using the superDimensionnavigation system. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024177 |